- Home
- QUIK vs HURA Comparison
QUIK vs HURA Comparison
Compare QUIK & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUIK
- HURA
- Stock Information
- Founded
- QUIK 1988
- HURA 2009
- Country
- QUIK United States
- HURA United States
- Employees
- QUIK N/A
- HURA N/A
- Industry
- QUIK Semiconductors
- HURA
- Sector
- QUIK Technology
- HURA
- Exchange
- QUIK Nasdaq
- HURA Nasdaq
- Market Cap
- QUIK 100.1M
- HURA 103.3M
- IPO Year
- QUIK 1997
- HURA N/A
- Fundamental
- Price
- QUIK $6.17
- HURA $2.40
- Analyst Decision
- QUIK Strong Buy
- HURA Strong Buy
- Analyst Count
- QUIK 3
- HURA 2
- Target Price
- QUIK $10.87
- HURA $11.50
- AVG Volume (30 Days)
- QUIK 185.6K
- HURA 226.8K
- Earning Date
- QUIK 08-12-2025
- HURA 08-15-2025
- Dividend Yield
- QUIK N/A
- HURA N/A
- EPS Growth
- QUIK N/A
- HURA N/A
- EPS
- QUIK N/A
- HURA N/A
- Revenue
- QUIK $18,768,000.00
- HURA N/A
- Revenue This Year
- QUIK $11.58
- HURA N/A
- Revenue Next Year
- QUIK $40.23
- HURA N/A
- P/E Ratio
- QUIK N/A
- HURA N/A
- Revenue Growth
- QUIK N/A
- HURA N/A
- 52 Week Low
- QUIK $4.26
- HURA $1.80
- 52 Week High
- QUIK $13.36
- HURA $8.63
- Technical
- Relative Strength Index (RSI)
- QUIK 48.53
- HURA N/A
- Support Level
- QUIK $6.13
- HURA N/A
- Resistance Level
- QUIK $6.77
- HURA N/A
- Average True Range (ATR)
- QUIK 0.35
- HURA 0.00
- MACD
- QUIK -0.04
- HURA 0.00
- Stochastic Oscillator
- QUIK 26.57
- HURA 0.00
About QUIK QuickLogic Corporation
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.